{
  "bio": [
    "Lee Sang-hoon is the founder, chairman, CEO and chief research officer of South Korean biotechnology company ABL Bio.",
    "ABL Bio develops bispecific antibodies, which target two molecules simultaneously to improve treatment outcomes for cancer and neurodegenerative diseases.",
    "In November 2025, it signed a $2.6 billion technology-transfer deal with Eli Lilly related to ABL Bio's Grabody-B blood-brain-barrier-penetrating bispecific antibody technology.",
    "Lee founded ABL Bio in 2016 and listed it on Korea's Kosdaq stock exchange two years later."
  ],
  "about": []
}